Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

atoplab.com
 

Enter Stock Symbol:  

Alkermes plc (ALKS)

41.19 -0.45 (-1.08%)

10-15 10:58

Open:

41.48

Pre. Close:

41.64

High:

41.8

Low:

41.01

Volume:

161,306

Market Cap:

6397M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

43.321 - 43.608

43.608 - 43.867

Low:

40.544 - 40.903

40.903 - 41.228

Close:

41.09 - 41.651

41.651 - 42.158

Technical analysis  (as of: 2018-10-15 10:44:31 AM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 49.65     One year: 52.75

Support:

Support1: 38.23    Support2: 31.81

Resistance:

Resistance1: 42.51    Resistance2: 45.16

Pivot:

42.89

Moving Averages:

MA(5): 42.08     MA(20): 42.34

MA(100): 44.21     MA(250): 49.16

MACD:

MACD(12,26): -0.09     Signal(12,26,9): 0.01

%K %D:

%K(14,3): 10.16     %D(3): 26.09

RSI:

RSI(14): 42.72

52-Week:

High: 71.22  Low: 38.23  Change(%): -19.5

Average Vol(K):

3-Month: 57293  10-Days 53334

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ALKS has closed above bottom band by 11.0%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-09-10T07:46:50-04:00
Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

2018-09-10T07:00:00-04:00
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology

Shares Out. (M)

155.32

Shares Float (M)

153.45

% Held by Insiders

% Held by Institutions

Shares Short (K)

7208

Shares Short Prior Month (K)

Stock Financials

EPS

EPS Est. Current Year

-0.040

EPS Est. Next Year

0.450

EPS Est. Next Quarter

-0.010

Forward EPS

0.650

Book Value (p.s.)

5.590

PEG Ratio

9.00

Profit Margin

-12.94

Operating Margin

-8.89

Return on Assets (ttm)

-8.0

Return on Equity (ttm)

-11.8

Qtrly Rev. Growth

39.2

Gross Profit (p.s.)

2.693

Sales Per Share

EBITDA (p.s.)

0.203

Qtrly Earnings Growth

Operating Cash Flow (M)

60.68

Levered Free Cash Flow (M)

37.46

Valuation

P/E

P/E Growth Ratio

P/BV

7.42

P/S

971152000.00

P/CF

106.12

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.